ERBB2 and breast carcinoma: However, the failure to achieve pCR, with the presence of residual tumor, does not necessarily confer a poorer prognosis than pCR for luminal breast cancer, in contrast to HER-2 and TN breast cancers; indeed, non-pCR has been associated with better survival than pCR for this tumor subtype (29), suggesting that TILs play a distinct functional role in eradicating luminal tumor cells after endocrine therapy.